Department of Health Management and Informatics, University of Central Florida, Orlando, USA.
Department of Internal Medicine (Joint Secondary Appointment), University of Central Florida, Orlando, USA.
Drug Alcohol Rev. 2020 Jul;39(5):583-587. doi: 10.1111/dar.13090. Epub 2020 May 11.
People with opioid use disorder are prevalent in criminal problem-solving courts and dependency courts, which have rehabilitative aims. Medication for opioid use disorder (MOUD) is the standard of care. Court staff set treatment policies for court clients. They may receive training from MOUD manufacturers, but no studies have examined court staff receipt of such training.
To examine receipt of training from MOUD manufacturers, we designed a cross-sectional survey for court staff. We distributed it online to all Florida court staff in criminal problem-solving or dependency courts (n = 585). Outcome variables were receipt of training from one or more MOUD manufacturers and training source. Covariates included dichotomous measures of court type, staff role, gender and rurality. Logistic regression models estimated the relationship between receipt of training and covariates.
Twenty-one percent of Florida criminal problem-solving and dependency court staff completed the survey. The most common receipt of training was from the manufacturer of extended-release naltrexone (36%), followed by buprenorphine (24%) and methadone (11%). Fifty-seven percent of those who received training received it from more than one MOUD manufacturer. Criminal problem-solving court staff were more likely than dependency court staff to receive training from MOUD manufacturers. Court program co-ordinators were more likely than other staff roles to receive training from MOUD manufacturers.
A large minority of respondents received training from a MOUD manufacturer, primarily from extended-release naltrexone's manufacturer, raising concerns regarding information accuracy and conflicts of interest. Court staff should seek MOUD training from academic institutions and non-profit organisations instead.
患有阿片类药物使用障碍的人在刑事解决法庭和依赖法庭中很常见，这些法庭都有康复的目的。阿片类药物使用障碍的药物治疗（MOUD）是标准的治疗方法。法庭工作人员为法庭客户制定治疗政策。他们可能会接受 MOUD 制造商的培训，但尚无研究检查过法庭工作人员是否接受过此类培训。
为了检查是否从 MOUD 制造商那里获得培训，我们为法庭工作人员设计了一项横断面调查。我们将其在线分发给佛罗里达州所有刑事解决或依赖法庭的法庭工作人员（n=585）。结果变量是接受一个或多个 MOUD 制造商培训和培训来源。协变量包括法庭类型、工作人员角色、性别和农村性别的二分变量。逻辑回归模型估计了接受培训与协变量之间的关系。
21%的佛罗里达州刑事解决和依赖法庭工作人员完成了调查。最常见的培训来自于纳曲酮的制造商（36%），其次是丁丙诺啡（24%）和美沙酮（11%）。57%接受培训的人接受了来自多个 MOUD 制造商的培训。刑事解决法庭工作人员比依赖法庭工作人员更有可能从 MOUD 制造商那里获得培训。法庭计划协调员比其他工作人员角色更有可能从 MOUD 制造商那里获得培训。
少数受访者接受了 MOUD 制造商的培训，主要是纳曲酮的制造商，这引发了人们对信息准确性和利益冲突的担忧。法庭工作人员应该从学术机构和非营利组织而不是 MOUD 制造商那里寻求 MOUD 培训。
